Mehta Named Deputy Director at Miami Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MINESH MEHTA joined Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology.

Mehta comes to Baptist Health from the University of Maryland School of Medicine, where he served as medical director of the Maryland Proton Treatment Center in Baltimore—the area’s first proton treatment center, which he helped to launch.

Mehta was also the university’s associate director of clinical research in the Department of Radiation Oncology. Prior to his time at Maryland, he held academic, research and administrative leadership positions at Northwestern University and the University of Wisconsin, where he was appointed chairman of the medical school’s Department of Human Oncology and led research studies, technology development and expansion at the University of Wisconsin Cancer Center. He also headed the university’s brain tumor program for more than 15 years. At the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Mehta was co-director of the Radiation Oncology Residency Training Program.

The Miami Cancer Institute’s new $430-million proton therapy facility, opening in 2016 and located on the Baptist Hospital of Miami campus, expects to treat its first patient with proton therapy in 2017.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login